Meeting
2018 ASCO Annual Meeting
Efficacy and safety of apatinib in advanced soft tissue sarcoma: A multi-center, open-label phase II clinical trial.
Authors
Wenxi Yu
Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
Wenxi Yu , Zhengfu Fan , Jing Chen , Hong-Mei Zhang , Xing Zhang , Guofan Qu , Yong Chen , Gang Huang , Yang Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03064243
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11546)
DOI
10.1200/JCO.2018.36.15_suppl.11546
Abstract #
11546
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Apatinib for patients (pts) with advanced soft tissue sarcoma (STS) after chemotherapy: A prospective, open-label, single-arm, multicentered study.
First Author: Haiyan Hu
Poster
2024 ASCO Annual Meeting
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
First Author: Jie Liu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
First Author: Lu Si
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang